We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
Read MoreHide Full Article
With the end of the pandemic, sales of Pfizer’s (PFE - Free Report) COVID products, Comirnaty and Paxlovid, declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, recent launches and newly acquired products like Nurtec and those from Seagen (December 2023).
The year 2023 was a record year for Pfizer in terms of new drug approvals. It received nine new medicine/vaccine approvals in 2023 that have begun to contribute to top-line growth. In 2024, it gained approval for a gene therapy for hemophilia, Hympavzi (marstacimab). In December 2023, Pfizer acquired Seagen, which strengthened its position in oncology by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in 2024 and 2025 so far. Seagen also has some next-generation ADC candidates in its pipeline.
Pfizer's recently launched and acquired products rose approximately 9% operationally in the first nine months of 2025, with the momentum expected to continuein 2026.
Pfizer faces some near-term challenges, including softness in sales of its COVID products, U.S. Medicare Part D headwinds and the upcoming loss of exclusivity (LOE) cliff in the 2026-2030 period. However, Pfizer’s key drugs like Vyndaqel, Padcev and its recently launched and acquired products should help the company largely offset its LOEs over the next several years. Pfizer expects the 2025 to 2030 revenue CAGR to be approximately 6% despite the LOE cliff.
Competition in the Oncology Space
Pfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the nine months of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $23.3 billion in the first nine months of 2025, up 8% year over year.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 8% to $7.54 billion in the nine months of 2025.
PFE’s Stock Price, Estimates & Valuation
Pfizer’s stock has declined 8% so far this year against an increase of 15.2% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 7.76 forward earnings, lower than 16.91 for the industry and the stock’s 5-year mean of 10.47.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $3.07 per share to $3.14, while that for 2026 has declined from $3.15 per share to $3.14 over the past 30 days.
Image: Bigstock
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
With the end of the pandemic, sales of Pfizer’s (PFE - Free Report) COVID products, Comirnaty and Paxlovid, declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, recent launches and newly acquired products like Nurtec and those from Seagen (December 2023).
The year 2023 was a record year for Pfizer in terms of new drug approvals. It received nine new medicine/vaccine approvals in 2023 that have begun to contribute to top-line growth. In 2024, it gained approval for a gene therapy for hemophilia, Hympavzi (marstacimab). In December 2023, Pfizer acquired Seagen, which strengthened its position in oncology by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in 2024 and 2025 so far. Seagen also has some next-generation ADC candidates in its pipeline.
Pfizer's recently launched and acquired products rose approximately 9% operationally in the first nine months of 2025, with the momentum expected to continuein 2026.
Pfizer faces some near-term challenges, including softness in sales of its COVID products, U.S. Medicare Part D headwinds and the upcoming loss of exclusivity (LOE) cliff in the 2026-2030 period. However, Pfizer’s key drugs like Vyndaqel, Padcev and its recently launched and acquired products should help the company largely offset its LOEs over the next several years. Pfizer expects the 2025 to 2030 revenue CAGR to be approximately 6% despite the LOE cliff.
Competition in the Oncology Space
Pfizer is one of the largest drugmakers of cancer medicines. Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the nine months of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $23.3 billion in the first nine months of 2025, up 8% year over year.
Bristol-Myers’ key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 8% to $7.54 billion in the nine months of 2025.
PFE’s Stock Price, Estimates & Valuation
Pfizer’s stock has declined 8% so far this year against an increase of 15.2% for the industry.
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 7.76 forward earnings, lower than 16.91 for the industry and the stock’s 5-year mean of 10.47.
The Zacks Consensus Estimate for 2025 earnings has risen from $3.07 per share to $3.14, while that for 2026 has declined from $3.15 per share to $3.14 over the past 30 days.
Pfizer currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.